Novo Nordisk to test diabetes tablet against Eli Lilly drug

A clinical trial will compare the effect of Novo Nordisk’s semaglutide with Eli Lilly’s Jardiance on patients’ blood sugar levels and body weight.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by christian bundgaard, translated by daniel pedersen

In a new clinical study, Novo Nordisk is seeking to measure the efficacy and safety of a once-daily tablet version of semaglutide, comparing the drug to Eli Lilly’s daily tablet treatment, empagliflozin, according to a filing on database Clinical Trials.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading